Trevena (NASDAQ:TRVN – Get Free Report) is expected to announce its resultson Thursday, November 5th. Analysts expect the company to announce earnings of ($50.00) per share and revenue of $0.78 million for the quarter.
Trevena Price Performance
Shares of TRVN stock opened at $0.01 on Tuesday. The firm has a market cap of $10,644.90, a P/E ratio of -0.00 and a beta of -0.55. Trevena has a 1-year low of $0.00 and a 1-year high of $1.50. The firm’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.01.
Trevena Company Profile
Trevena, Inc is a biopharmaceutical company focused on developing medicines for the treatment of acute and chronic pain, as well as disorders of the central nervous system. The company’s research has centered on G protein–coupled receptors and its “biased ligand” drug-discovery platform, which is intended to produce therapeutic effects while potentially reducing certain side effects associated with conventional treatments.
Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an opioid analgesic approved by the U.S.
Further Reading
- Five stocks we like better than Trevena
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
